abatacept
abatacept: 11 clinical trials tracked.
abatacept evidence translation
What we can confirm
11 tracked trials
What it means
What to watch
Prepared research question
What is verified about abatacept, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence7 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Clinical Trial Registry Records (11)showing 10 most recent
Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease
Primary endpoint: GVHD-free and rejection free survival (GRFS)
A Phase I Trial of Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma
Primary endpoint: Arm 2: To estimate the CRR of the combination of azacitidine and abatacept.
Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis
Primary endpoint: Number of participants with MiDA
An Open-Label Phase I Study of JAK Inhibitor Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
Primary endpoint: Cumulative incidence of graft failure
Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes
Primary endpoint: C-Peptide Response to 2-hr MMTT at 24 months post-randomization
Abatacept Combined With Nasal Insulin to Preserve Beta-cell Function in Recently-diagnosed Type 1 Diabetes
Primary endpoint: Beta-cell function at 48 weeks
A Randomized Double-Blind Trial of Abatacept Extended Dosing Versus Abatacept Short-term Dosing for Graft Versus Host Disease Prophylaxis: "ABA3"
Primary endpoint: Severe AGVHD-free, severe CGVHD-free, relapse-free survival (SGRFS)
Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease
Primary endpoint: High Resolution CT Scan of the chest (HRCT)
Acute GVHD Suppression Using Costimulation Blockade to Expand Non-malignant Transplant (ASCENT)
Primary endpoint: Event-free survival
To Demonstrate the Ability of Abatacept in Comparison to Placebo to Obtain a Low Disease Activity [PMR-AS (CRP) Lower or Equal to 10] Without GCs (Prednisone or Prednisolone) at Week 12 in Early Onset PMR Patients.
Primary endpoint: Following of one biological parameter (CRP)